On September 2, Regeneron Pharmaceuticals rose 3.05% in regular trading, trading at $848.935/share, with turnover of $219 million.

On the news front, RBC Capital Markets published a report indicating that Regeneron may broaden its long-running drug partnership with Sanofi to include several new immunology medicines. Currently, the collaboration only covers Dupixent and Kevzara, and both companies have expressed openness to renegotiating the agreement. RBC noted that Regeneron could seek a more even global profit-split arrangement, shifting away from the current structure in which Sanofi funds most development costs upfront while Regeneron reimburses those expenses over time. Additional pipeline drugs could potentially be folded into the partnership with updated financial terms. However, RBC cautioned that financial benefits from any expanded deal would likely take time to materialize, and maintained its sector-perform rating on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)